Oxford Nanopore Technologies

Oxford Nanopore Technologies From portable to population scale, nanopore devices offer direct analysis of DNA/RNA in-real time ?

17/06/2026

Thomas Alexander shared a case where biopsy gave no clear answer and pathology opinions conflicted. Running the sample on adaptive sequencing identified a difficult-to-find myeloid leukaemia fusion within days, helping avoid inappropriate chemotherapy.

Learn more: https://nanoporetech.com/resource-centre/from-innovation-to-global-impact-adaptive-genome-sequencing-for-childhood-leukemia-lc26?utm_campaign=Clinical+cancer+26&utm_content=1781701080&utm_medium=social&utm_source=facebook

Research use only.

For children with aggressive cancers, faster answers matter. Marilyn Li and her team at Children’s Hospital of Philadelp...
12/06/2026

For children with aggressive cancers, faster answers matter. Marilyn Li and her team at Children’s Hospital of Philadelphia are applying real-time Oxford sequencing to classify acute and CNS in minutes.

In this webinar, Marilyn Li will share data from their study, highlighting how gold-standard direct calling with Oxford Nanopore sequencing has the potential to reshape research.

Watch the webinar here: https://nanoporetech.com/about/events/knowledge-exchange/translational-and-clinical-applications-of-long-read-sequencing-technologies-in-oncology?utm_campaign=Clinical+cancer+26&utm_content=1781265660&utm_medium=social&utm_source=facebook

For research use only.

Oxford Nanopore's EPI2ME platform is enabling some of the world's most ambitious genomics programmes, processing thousan...
09/06/2026

Oxford Nanopore's EPI2ME platform is enabling some of the world's most ambitious genomics programmes, processing thousands of whole human genomes in the cloud, securely, reproducibly, and at half the cost of traditional approaches.

Singapore's PRECISE-SG100K cohort is sequencing over 10,000 whole genomes across Singapore's diverse population, one of the most ambitious national genomics programmes underway today.

To support this, Oxford Nanopore's EPI2ME team worked with AWS to deploy our wf-human-variation workflow on AWS Batch and Mountpoint for Amazon S3. The result is a 50% reduction in total cost of ownership, with no compromise on performance or reproducibility, and strict data sovereignty requirements met throughout.

By combining Oxford Nanopore's high-throughput sequencing, EPI2ME's orchestrated workflows, and AWS's scalable, secure, and reliable infrastructure, Singapore's NPM programme now runs end-to-end automated Oxford Nanopore genome analysis at population scale.

Learn more here: https://aws.amazon.com/blogs/hpc/reducing-costs-by-50-while-processing-population-scale-genomics-with-mountpoint-for-amazon-s3-and-aws-batch/

28/05/2026

At the Centre for Human Genetics in Belgium, researchers are demonstrating the potential of Oxford Nanopore sequencing to accelerate rare disease diagnostics.

Through the ELRIN project, they are integrating massive genomic datasets across Europe to uncover causative variants in developmental disorders—helping clinicians diagnose even the rarest conditions more effectively.

Learn more about Oxford Nanopore sequencing for rare disease research: https://nanoporetech.com/rare-disease?utm_campaign=Human+rare+26&utm_content=1779970260&utm_medium=social&utm_source=facebook

Oxford Nanopore is entering an important phase of scaling, where we aim to combine breakthrough innovation with the matu...
21/05/2026

Oxford Nanopore is entering an important phase of scaling, where we aim to combine breakthrough innovation with the maturing of our products and operations, so that we can deliver maximum impact for our users and their communities.

To help drive this journey, we’re strengthening our leadership team. We are pleased to share three senior appointments that will play a central role in how we grow and operate:

Andrew Watson will join as Chief Information Officer on 15 June, providing leadership across our information systems, digital transformation, machine learning and product software development. This will be critical as we deepen our use of machine learning in innovation, invest further in user experience, and drive operational efficiency at scale.

Davide Manissero MD will join as Chief Medical Officer in August, reflecting our increasing commitment to bringing rapid, information-rich omics to benefit clinical practice. He will lead our regulatory, quality, medical affairs and evidence generation functions to shape how we develop and deliver for clinical settings, deepening our engagement with clinicians and healthcare systems worldwide.

Tina St Leger joins us as Chief People Officer in June. She will lead how we continue to build organisational capability at scale: hiring, developing and connecting the people needed to sustain a high-performing, global company.

We’re excited to welcome Tina, Andrew and Davide to Oxford Nanopore.

Learn more: http://nanoporetech.com/news/oxford-nanopore-strengthens-executive-leadership-team?utm_campaign=&utm_content=1779386580&utm_medium=social&utm_source=facebook

21/05/2026

That’s a wrap on London Calling 2026, powered by innovative speakers and scientists rethinking what is possible.

From posters to focused breakouts, saw ideas turn into action. With 70+ speakers and thousands attending in person and online, this wasn’t one to miss.

See you next year.

Address

Oxford Science Park
Oxford
OX44GA

Opening Hours

Monday 9am - 11pm
Tuesday 9am - 11pm
Wednesday 9am - 11pm
Thursday 9am - 11pm
Friday 9am - 11pm

Telephone

+448450347900

Website

Alerts

Be the first to know and let us send you an email when Oxford Nanopore Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Oxford Nanopore Technologies:

Shortcuts

Share

Category